In blinded clinical trials the percentage of patients who experience muscle symptoms while taking a statin is typically in the 3-5% range. In practice, the percentage of patients who report muscle symptoms is 10-25%. This disparity between what has been observed in blinded trials and what patients experience when treated with a statin is due, in part, to the nocebo effect — a belief that a medication may cause harm. How many lives could be saved if we routinely used tiny randomized, controlled, blinded trials to determine when statin therapy can be safely continued?
Guest Panelists: Elizabeth Hearn, PharmD; Stuart T Haines PharmD, BCPS, BCACP; and Kathryn (Katie) Kiser, PharmD, BCACP
Music by Good Talk
SDOH Matters Too! Patient and Care Team Perspectives on Screening for SDOH
Treating Depression and Anxiety: Dosing, Pharmacogenetics, and Our Learners
Complex Patient Case 4: Diabetes, CKD, and Psoriasis
Can Losing Weight Using Semaglutide Prevent a Heart Attack, Ack, Ack, Ack, Ack?
Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.
Heartburn Headache: Cumulative PPI Use and Dementia Risk
Does Size Matter? The Surprising Impact of Cuff Size on Blood Pressure Readings
Defining the Role of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction
Do Statins “REPRIEVE” People Living with HIV from CV Events?
Top Ten Things Every Clinician Should Know About the RSV Vaccines
Complex Patient Case 3: Treatment Resistant Hypertension
Should We Be Good SPORTs About Supplements for Cholesterol?
Is Telehealth the Hidden (Hyper)Link to Controlling Blood Pressure?
Personalized Pharmacotherapy for Hypertension: Examining Intra-patient Variability
Over-the-Counter Hearing Aids – Where Do They Fit?
Road to Recovery: Pharmacist-Delivered Comprehensive Medication Management in an SUD Clinic
Gender Affirming Care - Finding the Resources You Need
Water Wars: Dueling Diuretics - Chlorthalidone vs. Hydrochlorothiazide for Cardiovascular Event Reduction
Beyond Statins: Approaches to Lipid Lowering in 2023
Fixed Dose or Treat-to-Target: Does LODESTAR Guide Us on Statin Management?
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Peter Attia Drive
THE MCCULLOUGH REPORT